|
KMID : 0388220130200060361
|
|
Journal of the Korean Rheumatism Association
2013 Volume.20 No. 6 p.361 ~ p.363
|
|
|
A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis
|
|
Choi Sang-A
|
|
|
Abstract
|
|
|
|
Treatments for patient with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (TNFα) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNFα agents in patients of end stage renal disease, especially those receiving peritoneal dialysis (PD), have not been investigated well, little is known about treating them with anti-TNFα agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.
|
|
|
KEYWORD
|
|
|
Ankylosing spondylitis , End-stage renal disease , Peritoneal dialysis , Tumor necrosis factor-alpha
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|